June 2025

How to generate microRNA sequence data from EVs

How to generate microRNA sequence data from EVs

Isolating EVs in a form compatible with downstream next-generation sequencing (NGS), particularly for small RNA analysis, can be technically challenging. But using the right kits to process the samples, many different groups have now developed an efficient workflow that is generating valuable EV microRNA data.

Read More

Can CAR-T cells succeed in solid cancers?

Can CAR-T cells succeed in solid cancers?

We explore the status of CAR T-cell therapy in the treatment of solid tumors, possible causes of failure, potential solutions, and the progress of CAR T-cell therapy for solid tumors and discuss the possible significance of CAR T-cell therapy for cancer treatment in the future.

Read More

iNKing out cancer: A better CAR-T cell?

iNKing out cancer: A better CAR-T cell?

CAR-T has been revolutionary, but as an autologous therapy, it is slow and costly. Allogeneic CAR-T cells, known as iNKTS, are now in development and may offer a rapid, cheaper (and perhaps more effective) off-the-shelf solution.

Read More

PROTACs: Degrading can be good

PROTACs: Degrading can be good

Targeted protein degradation (TPD) is an emerging technique used to study cellular processes and develop new therapies. Introduced in 1999, TPD works by breaking down specific proteins using either the proteasomal or lysosomal pathways. Most current TPD methods, such as PROTACs, molecular glues, Trim-Away, and SNIPERs, depend on the ubiquitin-proteasome system (UPS) and are primarily designed to target proteins inside cells.

Read More